Condition

Follicular Lymphoma clinical trials and research

• 68Clinical trials
• 9NIH research projects
• 35Countries

Newest Follicular Lymphoma clinical trials

All recruiting trials (68)

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• MK-1045 and Rituximab in Follicular Lymphoma

  This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.

  Recruiting at 38 sites Phase 2/3 Merck Sharp & Dohme LLC · Duarte, California and 37 other locations · NCT07634471

• Mosunetuzumab and Zeprumetostat in Follicular Lymphoma

  This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07555470

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• LY4584180 with rituximab for adults with previously treated B‑cell lymphomas

  This trial will test LY4584180 together with rituximab in adults with previously treated B‑cell lymphomas to see if it is safe, reaches useful levels in the blood, and can help control the disease.

  Recruiting at 21 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 45 other locations · NCT07226843

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Mosunetuzumab by subcutaneous injection as first-line therapy for low tumor burden follicular lymphoma

  This trial tests whether subcutaneous mosunetuzumab can be safely and effectively used as initial treatment for adults with newly diagnosed follicular lymphoma with low tumor burden.

  Recruiting at 4 sites Phase 2 Tel-Aviv Sourasky Medical Center · Haifa and 3 other locations · NCT07191249

• Odronextamab for previously untreated low-tumor-volume advanced follicular lymphoma

  This study will try odronextamab, an antibody immunotherapy, in adults with previously untreated low-tumor-volume advanced follicular lymphoma to see if it is safe and effective.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07128641

• Fixed-duration zanubrutinib plus bendamustine and obinutuzumab for newly diagnosed advanced follicular lymphoma

  This tests a six-cycle combination of zanubrutinib, bendamustine, and obinutuzumab for adults with newly diagnosed advanced-stage follicular lymphoma.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07126678

• Reduced-dose radiation therapy for people with follicular or marginal zone lymphoma

  This trial will test whether very low-dose radiation controls stage I–II follicular or marginal zone lymphoma as well as standard-dose radiation while causing fewer side effects.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07029217

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Golcadomide plus rituximab versus investigator's choice for relapsed or refractory follicular lymphoma

  This trial tests whether combining golcadomide with rituximab works better than standard investigator‑selected treatments for adults with relapsed or refractory follicular lymphoma who have had at least one prior systemic therapy.

  Recruiting at 62 sites Phase 3 Celgene · Birmingham, Alabama and 159 other locations · NCT06911502

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• ImmunoPET imaging for detecting malignant cancers

  This study is testing a new imaging method to see if it can better detect certain types of cancer in patients who have or might have these diseases.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT06852638

• Assessing Epcoritamab for Adult Patients with Advanced Lymphoma

  This study is testing if a new skin injection called epcoritamab can help adults with advanced lymphoma feel better and improve their health.

  Recruiting at 73 sites AbbVie · Ciudad Autonoma de Buenos Aire, Buenos Aires and 72 other locations · NCT06830759

• Treatment for patients with relapsed follicular lymphoma using Axicabtagene Ciloleucel Injection

  This study is testing a new treatment called Axicabtagene Ciloleucel Injection to see if it can help Chinese patients with relapsed follicular lymphoma who have already tried other therapies.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06826118

• Long-term safety of lisocabtagene maraleucel in patients with relapsed follicular lymphoma

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed follicular lymphoma who have already received it.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06794268

• Tafasitamab with lenalidomide and rituximab for newly diagnosed follicular and marginal zone lymphoma

  This trial will test whether adding tafasitamab to rituximab and lenalidomide is safe and helps people newly diagnosed with follicular lymphoma or marginal zone lymphoma.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06792825

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Radiation and Tiselizumab with RCHOP for Bulky Follicular Lymphoma

  This study is testing if adding radiation to a combination of Tiselizumab and R-CHOP chemotherapy can help people with bulky follicular lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06704555

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Combining Zanubrutinib and Obinutuzumab for Treating Newly Diagnosed Follicular Lymphoma

  This study is testing a new combination of two medications, Zanubrutinib and Obinutuzumab, to see if they can help people with newly diagnosed follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06553352

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Epcoritamab treatment for patients with follicular lymphoma not responding to initial therapy

  This study is testing if a new treatment called epcoritamab can help people with follicular lymphoma who didn't respond well to their first therapy.

  Recruiting at 3 sites Phase 2 Beth Israel Deaconess Medical Center · Stanford, California and 2 other locations · NCT06510361

• Combining rituximab and zanubrutinib for treating indolent B-cell lymphomas

  This study is testing if combining two medications, rituximab and zanubrutinib, can help people with untreated indolent B-cell lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06350318

• Using CAR T cells to treat certain types of B cell lymphomas

  This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06340737

• Observational study on CAR-T therapy for lymphoma in Italy

  This study looks at how well CAR-T therapy works and its side effects for people with lymphoma in Italy by tracking their health over three years.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06339255

• Combining Chidamide and Linperlisib for treating difficult cases of follicular lymphoma

  This study is testing if combining two drugs, Chidamide and Linperlisib, can help people with tough cases of follicular lymphoma who haven't responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06158386

• Combining lenalidomide with G-CHOP for treating newly diagnosed DLBCL with FL

  This study is testing if adding lenalidomide to the G-CHOP treatment can help people newly diagnosed with diffuse large B-cell lymphoma and follicular lymphoma feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06151080

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Treatment for high tumor burden follicular lymphoma using obinutuzumab and CC-99282

  This study is testing if a new combination of obinutuzumab and CC-99282 can help people with high tumor burden follicular lymphoma who haven't been treated before feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06108232

• Combining CAR T-cell therapy with radiation for relapsed follicular lymphoma

  This study is testing if combining a new CAR T-cell therapy with radiation can help people with relapsed follicular lymphoma feel better and have fewer side effects.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06043323

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Testing ONM-501 alone and with Cemiplimab for advanced solid tumors and lymphomas

  This study is testing a new treatment called ONM-501, both alone and with another drug called cemiplimab, to see if it can help people with advanced solid tumors and lymphomas who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 OncoNano Medicine, Inc. · Los Angeles, California and 15 other locations · NCT06022029

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Comparing radiotherapy alone versus with Obinutuzumab for early stage follicular lymphoma

  This study is testing if adding Obinutuzumab to radiation therapy helps people with early-stage follicular lymphoma do better than just radiation alone.

  Recruiting at 43 sites Phase 3 Fondazione Italiana Linfomi - ETS · Sassuolo, Modena (MO) and 48 other locations · NCT05929222

• Observing the effects of obinutuzumab for untreated follicular lymphoma

  This study looks at how well the drug obinutuzumab works and how safe it is for people with untreated follicular lymphoma in real-life settings.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05899621

• Combining obinutuzumab and lenalidomide for treating relapsed follicular lymphoma

  This study is testing if combining obinutuzumab and lenalidomide can help people in China with relapsed follicular lymphoma feel better and live longer, while keeping their current treatment plans.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05846763

• Evaluating biomarkers in advanced follicular lymphoma treatment

  This study is trying to see if certain genetic changes in patients with advanced follicular lymphoma can help doctors choose the best chemotherapy treatment after they've received immunotherapy.

  Recruiting at 19 sites Fondazione Italiana Linfomi - ETS · Alessandria and 25 other locations · NCT05816850

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Epcoritamab plus rituximab as first treatment for follicular lymphoma

  This trial tests whether adding epcoritamab to rituximab is safe and effective as the first treatment for adults with untreated follicular lymphoma.

  Recruiting at 6 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 5 other locations · NCT05783609

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Evaluating the effectiveness and safety of tisagenlecleucel therapy in Brazilian patients with B-cell malignancies

  This study is testing how well and safely a treatment called tisagenlecleucel works for Brazilian patients with certain types of blood cancers, including lymphoma and leukemia, over a long follow-up period.

  Recruiting at 7 sites Novartis · Minas Gerais, Belo Horizonte and 6 other locations · NCT05541341

• Treatment with Mosunetuzumab for newly diagnosed Follicular Lymphoma

  This study is testing if a new treatment called mosunetuzumab can help people who have just been diagnosed with follicular lymphoma feel better before they start other treatments.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Washington D.C., District of Columbia and 8 other locations · NCT05389293

• IKS03 treatment for advanced B cell non-Hodgkin lymphomas

  This study is testing a new treatment called IKS03 for people with advanced B cell non-Hodgkin lymphoma to see how safe and effective it is.

  Recruiting at 12 sites Phase 1 Iksuda Therapeutics Ltd. · Baltimore, Maryland and 12 other locations · NCT05365659

• Evaluating zanubrutinib treatment in patients with certain blood cancers

  This study is trying to see how well zanubrutinib works and how it affects the lives of adults with certain blood cancers like Waldenström's Macroglobulinemia and Chronic Lymphocytic Leukemia.

  Recruiting at 2 sites iOMEDICO AG · Salzburg and 1 other locations · NCT05326308

• Treatment for B-cell malignancies using BGB-16673

  This study is testing a new drug called BGB-16673 to see if it can safely help people with different types of B-cell cancers.

  Recruiting at 29 sites Phase 1/2 BeOne Medicines · Bengbu, Anhui and 28 other locations · NCT05294731

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Assessing ctDNA for monitoring lymphoma patients receiving CAR therapy

  This study is testing if measuring tumor DNA in the blood can help doctors keep track of lymphoma patients receiving CAR therapy and see if their cancer is coming back sooner than traditional scans.

  Recruiting Adaptive Biotechnologies · Palo Alto, California · NCT05255354

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Combining Loncastuximab Tesirine and Rituximab for treating relapsed Follicular Lymphoma

  This study is testing if combining two treatments, Loncastuximab Tesirine and Rituximab, can help people with relapsed Follicular Lymphoma feel better compared to current options.

  Recruiting at 3 sites Phase 2 University of Miami · Fort Myers, Florida and 4 other locations · NCT04998669

• Orelabrutinib plus rituximab followed by orelabrutinib maintenance for relapsed or refractory follicular lymphoma

  This trial tests whether combining orelabrutinib with rituximab, followed by orelabrutinib alone, helps people whose follicular lymphoma has come back or stopped responding.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT04989621

• First-line treatment for follicular and marginal zone lymphoma using mosunetuzumab and lenalidomide

  This study is testing if a new combination of treatments can help adults with untreated follicular or marginal zone lymphoma feel better and improve their response to therapy.

  Recruiting at 2 sites Phase 2 Brown University · New Haven, Connecticut and 2 other locations · NCT04792502

• Oral treatment with LP-168 for patients with certain blood cancers

  This study is testing an oral treatment called LP-168 to see if it can help adults with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 4 sites Phase 1 Newave Pharmaceutical Inc · Durham, North Carolina and 3 other locations · NCT04775745

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• Treatment using modified T cells for certain types of lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with certain types of lymphoma that haven't responded to other therapies.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT04223765

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

• Treatment for relapsed or refractory CD19+ lymphoid diseases using engineered T cells

  This study is testing a new treatment using specially modified immune cells to help adults and children with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 2 sites Phase 1/2 University Hospital Heidelberg · Heidelberg and 1 other locations · NCT03676504

• Evaluating immune responses to influenza vaccination in lymphoma patients

  This study is testing how well the flu vaccine works for people with lymphoma by checking their immune responses after getting vaccinated.

  Recruiting at 2 sites Emory University · Atlanta, Georgia and 1 other locations · NCT03501576

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Long-term follow-up of patients receiving CAR-T cell therapy

  This study is tracking patients who have received CAR-T cell therapy for up to 15 years to see how well the treatment works over time and if there are any long-term health issues.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT03375619

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

• Understanding the progression of follicular lymphoma

  This study is trying to learn more about how follicular lymphoma develops in adults who haven't started treatment yet, by collecting samples and information to help find better treatments in the future.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03190928

NIH-funded research (9)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Preventing follicular lymphoma progression with precision therapy

  This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.

  NIH research New York University School of Medicine · New York, United States · NIH-11504820

• Follicular Lymphoma: Better Diagnosis and Personalized Risk in B-Cell Lymphomas

  This NIH grant aims to improve how doctors diagnose and predict outcomes for people with follicular lymphoma by finding reliable biomarkers to guide treatment decisions.

  NIH research New York University School of Medicine · New York, United States · NIH-11402045

• IRF4's role in shaping the tumor environment in follicular lymphoma

  This grant aims to understand how a molecule called IRF4 changes the tumor surroundings in follicular lymphoma to identify potential new ways to help patients.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11378260

• Gene test to predict early treatment failure in follicular lymphoma

  A lab test that reads genes in lymphoma biopsy tissue to spot people with follicular lymphoma who are likely to have their disease return within two years after standard immunochemotherapy.

  NIH research University of Arizona · Tucson, United States · NIH-11195009

• How mutant STAT6 affects follicular lymphoma

  This project looks at how a gene change called STAT6 affects follicular lymphoma to help find better treatments for people with this cancer.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11169832

• Preventing the progression of follicular lymphoma with targeted therapy

  This study is looking at how slow-growing follicular lymphomas can change into more aggressive forms, and it's working to find personalized treatments that target the specific factors that help these tumors survive, so we can help patients live better and longer.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11109606

• Developing a test to predict early treatment failure in follicular lymphoma

  This study is looking to help doctors better predict which patients with follicular lymphoma might not respond well to standard treatment, using a special test on tissue samples to find important genetic clues, so they can create more personalized treatment plans for you.

  NIH research University of Arizona · Tucson, United States · NIH-10947165

• Understanding how mutant STAT6 affects follicular lymphoma

  This study is looking at how certain changes in a gene called STAT6 affect follicular lymphoma, a type of cancer, to help find better treatments that work for patients based on their unique genetic makeup.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-10896187

• Understanding how IRF4 affects the tumor environment in follicular lymphoma

  This study is looking at how a protein called IRF4 affects the environment around tumors in people with follicular lymphoma, a type of blood cancer, to find new ways to improve treatment and help patients feel better.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10806442

Related topics

Quick answers

How many Follicular Lymphoma clinical trials are recruiting right now?

68, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in United States (46 trials), China (16 trials), Italy (10 trials), Australia (7 trials), Spain (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 25, Phase 1: 13, Phase 1/2: 7, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →